Use of two-year disease-free survival (DFS) as a primary endpoint in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: New data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, NSAPB C-06 and C-07, and C89803 Meeting Abstract
| Authors: | Sargent, D. J.; Yothers, G.; Van Cutsem, E.; Cassidy, J.; Saltz, L.; Wolmark, N.; Shi, Q.; Buyse, M.; de Gramont, A. |
| Abstract Title: | Use of two-year disease-free survival (DFS) as a primary endpoint in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: New data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, NSAPB C-06 and C-07, and C89803 |
| Meeting Title: | 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 27 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2009 May 29-Jun 2 |
| Meeting Location: | Orlando, FL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2009-05-20 |
| Start Page: | 170s |
| Language: | English |
| ACCESSION: | WOS:000276606600253 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2009.27.15_suppl.4011 |
| Notes: | Meeting Abstract: 4011 -- Source: Wos |
